The European Commission granted an approval under exceptional circumstances to InflaRx’s immunosuppressant. The European ...

InflaRx receives European marketing authorization for Gohibicto treat of SARS-CoV-2-induced acute respiratory distress syndrome: Jena, Germany Friday, January 17, 2025, 11:00 Hrs ...

InflaRx (IFRX) has received EU regulatory approval for its treatment Gohibic for the treatment of COVID-19 patients ...

IFRX stock gains 8% on EC nod for Gohibic, under exceptional circumstances, to treat adult patients with COVID-19-induced ...

The following is a summary of “Prognostic role of cardiac and inflammatory biomarkers in extubation failure in patients with COVID-19 acute respiratory distress syndrome,” published in the January ...

InflaRx (IFRX) announced that the European Commission has granted marketing authorization under exceptional circumstances for Gohibic for the ...

Methods: We used the Medline database to select studies with the key words “acute lung ... of patients with ALI/ARDS over the last 10 years. Importantly, ARDS is a syndrome and not an illness ...

Leerink Partners analyst Joseph Schwartz has maintained their bullish stance on IFRX stock, giving a Buy rating yesterday.Stay Ahead of the ...

H.C. Wainwright reaffirmed its Buy rating and $8.00 price target for InflaRx NV (NASDAQ:IFRX), following the European ...

• hMPV: Milder symptoms like nasal congestion, wheezing, and cough are common; severe cases like bronchiolitis or pneumonia ...

In cases of pre-eclampsia, placental abruption, haemolysis, elevated liver enzymes low platelets syndrome, and acute fatty liver of pregnancy, delivery of the foetus should be considered to reverse ...